Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice

Eur J Pharmacol. 1992 Feb 25;212(1):87-92. doi: 10.1016/0014-2999(92)90076-g.


The mechanism was studied by which isoliquiritigenin, a new aldose reductase inhibitor purified from licorice (Glycyrrhizae radix), inhibits platelet aggregation. This new agent significantly inhibited the phosphorylation of 40,000- and 20,000-dalton proteins, and inhibited the formation of 12 (S)-hydroxy-5,8,10-heptadecatrienoic acid, 12-hydroxyeicosatetraenoic acid and thromboxane B2. The inhibitory effect of isoliquiritigenin on platelet aggregation in vitro was comparable to that of aspirin. Our findings may indicate that isoliquiritigenin elicits an anti-platelet action by inhibiting not only cyclooxygenase but also lipoxygenase or peroxidase activity in platelets. Isoliquiritigenin also showed an anti-platelet action in vivo. Isoliquiritigenin appears to be the only aldose reductase inhibitor with a significant anti-platelet action. Since the hyperaggregability of platelets has been implicated in the pathogenesis of diabetic complications, isoliquiritigenin may offer a unique benefit as an aldose reductase inhibitor.

MeSH terms

  • Aldehyde Reductase / antagonists & inhibitors*
  • Blood Platelets / drug effects*
  • Blood Platelets / metabolism
  • Blood Proteins / metabolism*
  • Chalcone / analogs & derivatives*
  • Chalcone / chemistry
  • Chalcone / pharmacology
  • Chalcones
  • Fatty Acids, Unsaturated / blood
  • Glycyrrhiza / chemistry
  • Humans
  • Hydroxyeicosatetraenoic Acids / blood
  • Molecular Weight
  • Phosphorylation / drug effects
  • Plants, Medicinal
  • Platelet Aggregation Inhibitors / pharmacology*
  • Thromboxane B2 / blood


  • Blood Proteins
  • Chalcones
  • Fatty Acids, Unsaturated
  • Hydroxyeicosatetraenoic Acids
  • Platelet Aggregation Inhibitors
  • 12-hydroxy-5,8,10-heptadecatrienoic acid
  • Thromboxane B2
  • Chalcone
  • isoliquiritigenin
  • Aldehyde Reductase